Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy
The Phase I trial for evaluating Hemogenyx’s CAR-T therapy to treat acute myeloid leukaemia has been cleared to begin in the US.
The Phase I trial for evaluating Hemogenyx’s CAR-T therapy to treat acute myeloid leukaemia has been cleared to begin in the US.
What's Your Reaction?
